2018
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
Kim R, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaCTCL cellsBCL2 inhibitionCell lymphomaAdvanced cutaneous T-cell lymphomaHDAC inhibitionSkin-homing T cellsPromising novel therapeutic strategyBET inhibitionNon-Hodgkin lymphomaPotential novel therapyCTCL cell linesDose-dependent decreaseNovel therapeutic strategiesHistone deacetylase inhibitionExtraterminal protein inhibitorSystemic therapyLymph nodesPeripheral bloodNovel therapiesT cellsTherapeutic strategiesCaspase-3/7 activationAdvanced stage
2002
Transformation in mycosis fungoides: The role of methotrexate
Abd-el-Baki J, Demierre MF, Li N, Foss FM. Transformation in mycosis fungoides: The role of methotrexate. Journal Of Cutaneous Medicine And Surgery 2002, 6: 109-116. PMID: 11992182, DOI: 10.1007/s10227-001-0040-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCell Transformation, NeoplasticDermatologic AgentsFemaleGenes, T-Cell Receptor gammaHumansImmunophenotypingImmunosuppressive AgentsLymphoma, Large B-Cell, DiffuseMaleMethotrexateMiddle AgedMycosis FungoidesPolymerase Chain ReactionRetrospective StudiesSkin NeoplasmsSurvival AnalysisConceptsLarge cell lymphomaRole of methotrexateMycosis fungoidesCell lymphomaDominant T-cell cloneCutaneous lymphoma databaseT cell clonesIncidence of transformationLymphoma databaseImmunosuppressive therapyMTX groupMTX exposureShort followupMulticenter studyResultsA totalRisk factorsSkin biopsiesRare disorderHigh incidencePatientsAdvanced stageMethotrexateConclusionOur resultsSignificant associationSkin specimens